Lumicell Revenue and Competitors

Boston, MA USA

Location

$33M

Total Funding

Estimated Revenue & Valuation

  • Lumicell's estimated annual revenue is currently $8.3M per year.(i)
  • Lumicell received $28.7M in venture funding in December 2017.
  • Lumicell's estimated revenue per employee is $125,500
  • Lumicell's total funding is $33M.

Employee Data

  • Lumicell has 66 Employees.(i)
  • Lumicell grew their employee count by 2% last year.

Lumicell's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Pharmaceutical Development and CMC at LumicellReveal Email/Phone
3
VP, New Business Strategy and InnovationReveal Email/Phone
4
CHIEF COMMERCIAL OFFICER (CCO)Reveal Email/Phone
5
Senior Director Product DevelopmentReveal Email/Phone
6
President & Chief Scientific OfficerReveal Email/Phone
7
Senior Director FinanceReveal Email/Phone
8
Associate Director Distribution and Materials ManagementReveal Email/Phone
9
Chief Business & Strategy OfficerReveal Email/Phone
10
Manager - Device Quality and UsabilityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$8.5M343%N/AN/A
#3
$3M12-29%N/AN/A
#4
$5630M7477-11%$450MN/A
#5
$4.5M186%N/AN/A
#6
$7.2M5727%$29.6MN/A
#7
$14.3M57-12%N/AN/A
#8
$2.3M186%$44MN/A
#9
$40.7M162-1%N/AN/A
#10
$45.7M182-5%N/AN/A
Add Company

What Is Lumicell?

Lumicell is a leader in the field of image-guided cancer surgery. Lumicell technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, is currently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett's Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated.

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals

$33M

Total Funding

66

Number of Employees

$8.3M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lumicell News

2022-03-22 - Clinical Data on Lumicell's Direct Visualization System to Be ...

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve...

2019-09-12 - Innoblative taps ex-Lumicell chief Londy for CEO | Personnel ...

Innoblative Designs last week named former Lumicell chief executive Kelly Londy as its new CEO. Apart from her two-year stint at the Lumicell ...

2019-08-17 - Lumicell closes enrollment of feasibility trial

Lumicell said it completed enrollment in a Phase C feasibility clinical trial for its intraoperative breast cancer imaging system. The Newton, Mass ...

2019-06-19 - Lumicell Technology Improves Efficiency of Mesothelioma ...

Lumicell- Experts are testing a new innovative imaging technology at Massachusetts General Hospital. The imaging technology can enhance ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.3M6720%N/A
#2
$13.5M683%N/A
#3
$15.5M69-8%N/A
#4
$11.5M714%N/A
#5
$7.5M730%N/A

Lumicell Funding

DateAmountRoundLead InvestorsReference
2014-01-07$1.0MBArticle
2016-05-09$6.8MUndisclosedArticle
2017-07-13$UndisclosedUndisclosedArticle
2017-10-25$20.7MUndisclosedArticle
2017-12-08$28.7MCLaunch CapitalArticle